This site is intended for Healthcare professionals only.

Dehydrated Amniotic Membrane Allograft effective for Lower Extremity Wounds

Dehydrated Amniotic Membrane Allograft effective for Lower Extremity Wounds

Dr.Eric J. Lullove in a retrospective Cohort Study evaluated the effectiveness of a dHAM matrix for the treatment of lower extremity wounds as well as to evaluate the safety of the tissue’s use.The author found that use of  Dehydrated Amniotic Membrane Allograft was effective in closing diabetic foot ulcerations and other wounds of the foot.The study has been published in Wound.

Injuries to the skin are extensively costly to the healthcare system. When caused by metabolic and vascular compromise, these injuries are even more foreboding for patients. They can result in chronic inflammation, reduced mobility, and chronic pain and therefore an effective option for treating Lower Extremity Wounds has to be explored.

The researchers selected twenty patients from the author’s patient population at the West Boca Center for Wound Healing for a retrospective cohort study. Patients underwent a run-in period of 2 weeks, where the standard of care was used to clear the wound of bioburden. A dehydrated, human amniotic membrane (dHAM; WoundEx Membrane, Skye Biologics, Inc, El Segundo, CA) was applied at weeks 1 (2 weeks post run-in), 3, and 5, if necessary. Wound measurements and photographs were performed weekly. Data were collected through a standard form in each patient’s medical record to improve reliability and reproducibility. The data extraction was performed by the author and to reduce bias. Reduction of bias was performed by selecting patients whose wounds already were established and in temporal sequence.

 In the study , the author was able to effectively close all wounds in approximately 9.9 weeks (69.3 days). A linear relationship was discovered between wound size in cm[2] and days to closure. Diabetic foot ulcers closed on average in 11.8 weeks (82.6 days) and venous leg ulcers in 9.2 weeks (64.4 days). No adverse events were noted secondary to the dHAM application, which shows this is a safe and effective treatment option. As of the date of this publication, there is no recurrence of the ulcerations noted.

It was therefore concluded that use of this particular dHAM allograft effectively closed diabetic foot ulcerations in 82.6 days and median wound closure in 69.3 days. This poses as an advantageous clinical benefit in the scope of treatment of lower extremity wounds.While this is a small subset study, the author acknowledges a larger cohort study is necessary to validate the findings seen in this trial.

For further reference log on to :

Spread the love

Source: Press Release

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted